Is PCRX undervalued or overvalued?

As of 2025-03-26, the Intrinsic Value of Pacira Biosciences Inc (PCRX) is (36.70) USD. This PCRX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 24.54 USD, the upside of Pacira Biosciences Inc is -249.50%. This means that PCRX is overvalued by 249.50%.

The range of the Intrinsic Value is (120.05) - (24.67) USD

Note: result may not be accurate due to the invalid valuation result of DCF model.

	Range	Selected	Upside
a
DCF (Growth 5y)	(120.05) - (24.67)	(36.70)	-249.5%
DCF (Growth 10y)	(22.17) - (92.26)	(31.08)	-226.7%
DCF (EBITDA 5y)	(4.79) - (7.57)	(1,234.50)	-123450.0%
DCF (EBITDA 10y)	(4.95) - (0.78)	(1,234.50)	-123450.0%
Fair Value	-53.82 - -53.82	-53.82	-319.33%
P/E	(15.58) - (23.37)	(19.47)	-179.4%
EV/EBITDA	4.47 - 16.74	9.79	-60.1%
EPV	29.23 - 41.94	35.58	45.0%
DDM - Stable	(20.45) - (78.24)	(49.35)	-301.1%
DDM - Multi	(5.34) - (16.16)	(8.06)	-132.9%